黄葵胶囊联合依那普利治疗糖尿病肾病临床研究

Clinical Research of the Abelmosk Capsules Combined with Enalapril for the Treatment of Diabetic Nephropathy

目的:观察黄葵胶囊联合依那普利治疗糖尿病肾病的临床疗效。方法:将2013年2月—2015年2月本院收治的82例糖尿病肾病患者随机分为对照组和治疗组各41例。对照组患者给予马来酸依那普利片内服,每次10 mg,日1次;观察组患者则加用黄葵胶囊,每次5粒,日3次,连续治疗8周。观察患者治疗前后主要症状改善情况,检测治疗前后血糖、血脂、尿蛋白、肾功能、炎性因子水平。结果:两组患者胸脘腹胀、咽喉肿痛、头身困重、口黏口干等症状与治疗前比改善突出,证候积分降低,治疗组变化尤其明显,其有效率92.7%明显高于对照组73.1%,差异性显著(P<0.05);患者的糖脂代谢较治疗前有所改善,治疗组的血糖、血脂水平改善更为明显,差异性显著(P<0.05);治疗组患者的UTP、UAER、SCr、α1-MG、β2-MG水平低于治疗前及对照组患者,差异性显著(P<0.05);治疗组患者的炎性因子CRP、TNF-α、IL-6水平降低较对照组患者更为明显,差异性显著(P<0.05)。结论:黄葵胶囊联合依那普利治疗糖尿病肾病疗效确切。

ptoms of gastral and abdominal distension,swelling and sore throat,heaviness of the head and body,sticky and dry mouth got remarkably improved compared with before treatment. The symptom scores declined and the changes in treatment group were especially obvious with the effective rate of 92. 7%,which was apparently higher than 73. 1% in control group; the difference was significant（ P 〈0. 05）. The glucolipid metabolism got improved after the treatment. The improvement of the blood sugar and blood lipid in treatment group was much greater than that in control group; the difference was significant（ P 〈0. 05）. The levels of UTP,UAER,SCr,α1-MG and β2- MG in treatment group were lower than before treatment and these in control group; the difference was significant（ P 〈0. 05）. The decline of the levels of the inflammatory factors of CRP,TNF-α and IL-6 in treatment group was much more obvious than that in control group; the difference was significant（ P 〈0. 05）. Conclusion： Abelmosk Capsules combined with Enalapril have definite efficacy for the treatment of proteinuria of patients with DN.